Tasimelteon



- TRADE NAME: Hetlioz (Vanda)
- INDICATIONS: Non-24-hour sleep-wake disorder
- CLASS: Melatonin receptor agonist
- HALF-LIFE: 2–3 hours
FDA APPROVAL DATE: 01/31/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Fluvoxamine, Ketoconazole, Rifampin, Viloxazine
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric